Stock listing
Aim Vaccine Co., Ltd. Class H
Selected listing: 6660 · HKEX · HKD · HK
Aim Vaccine Co., Ltd. Class H (HKEX:6660), Health Technology. Latest release Feb 6, 2026: World's First Serum-Free Iterative Rabies Vaccine from AIM…
- Ticker
- HKEX:6660
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- HKEX
- Currency
- HKD
About Aim Vaccine Co., Ltd. Class H
The company focuses on the development and production of vaccines. Its operations are aimed at addressing public health needs through innovative vaccine solutions.
Latest news from Aim Vaccine Co., Ltd. Class H
World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch
February 5, 2026
AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities
January 19, 2026
AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products
January 14, 2026
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
August 27, 2025
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
May 18, 2025
Research Aim Vaccine Co., Ltd. Class H
Aim Vaccine Co., Ltd. Class H company profile
View the public company page for Aim Vaccine Co., Ltd. Class H on 6ix.
Aim Vaccine Co., Ltd. Class H news
Read company news and market updates connected to Aim Vaccine Co., Ltd. Class H.
Aim Vaccine Co., Ltd. Class H investor events
Find investor webinars, events, and replay context for Aim Vaccine Co., Ltd. Class H.